The company reported adjusted earnings of 78 cents per share for the second quarter, beating the analyst consensus estimate of 74 cents. Revenue increased to $1.741 billion from a year earlier, exceeding the $1.70 billion consensus estimate.
Total sales rose 13.6% year over year, or 12.5% on a constant-currency basis.
TAVR, TMTT Businesses Fuel GrowthTranscatheter Aortic Valve Replacement (TAVR) sales increased 11.3% year over year, or 10.5% in constant currency, to $1.3 billion.
The company said procedural growth benefited from sustained clinical momentum and growing evidence supporting earlier treatment of severe aortic stenosis. Growth was similar in the U.S. and international markets and also benefited from a competitor’s market exit in 2025.
Transcatheter Mitral and Tricuspid Therapies (TMTT) revenue climbed to $195.9 million, supported by continued demand for the company’s repair and replacement therapies. Edwards said mitral and tricuspid procedure growth remained in the double digits globally.
Surgical segment sales rose 6.5% from a year earlier to $284 million, or 5% in constant currency. The increase was driven by continued adoption of the company’s RESILIA tissue technologies.
Company Raises Revenue OutlookEdwards reaffirmed its fiscal 2026 adjusted earnings guidance of $2.95 to $3.05 per share. That range brackets the Wall Street consensus estimate of $3.01.
The company also raised the low end of its full-year revenue guidance. It now expects revenue of $6.60 billion to $6.90 billion, up from its previous forecast of $6.50 billion to $6.90 billion. The updated range brackets the Wall Street consensus estimate of $6.745 billion.
Edwards also reaffirmed its expectation for 2026 TAVR sales of $4.75 billion to $5.0 billion.
Analyst Sees More Upside AheadWilliam Blair analyst Brandon Vazquez said Friday that the results reinforced the firm’s bullish outlook on Edwards.
“Overall, the second quarter reaffirmed our bullish thesis on Edwards shares, offering one of the better setups for medtech growth,” Vazquez wrote.
The analyst maintained an Outperform rating, saying the stock, trading at about 26 times projected 2027 earnings, could see further upside as earnings grow and additional catalysts emerge in the second half of 2026 and into 2027.
EW Stock Price Activity: Edwards Lifesciences shares were up 3.32% at $86.60 at the time of publication on Friday, according to Benzinga Pro data.
Market News and Data brought to you by Benzinga APIs
Key Takeaways Edwards Lifesciences topped Q2 earnings and revenue estimates, with shares rising nearly 3% after hours.EW raised 2026 sales growth guidance as TAVR demand and TMTT adoption remained strong.Edwards Lifesciences reaffirmed 2026 earnings guidance and expects Q3 revenues of $1.63B-$1.71B. Edwards Lifesciences Corporation (EW - Free Report) reported second-quarter 2026 adjusted earnings of 78 cents per share, up 16.4% year over year. The figure surpassed the Zacks Consensus Estimate by 6.8%.
Revenues rose 13.6% to $1.74 billion and topped the consensus mark by 2.4%. Growth was driven by strong Transcatheter Aortic Valve Replacement (“TAVR”) demand and rapid adoption of the company’s mitral and tricuspid therapies.
Following the announcement yesterday, EW shares jumped nearly 3% in after-hours trading.
EW’s Segment Sales Reflect Broad-Based GrowthTAVR sales totaled $1.26 billion, up 11.3% year over year on a reported basis and 10.5% at constant currency. Growth was similar in the United States and international markets, supported by procedural momentum, clinical evidence favoring proactive treatment of severe aortic stenosis and continued adoption of the SAPIEN 3 Ultra RESILIA platform.
Transcatheter Mitral and Tricuspid Therapies (“TMTT”) sales reached $195.9 million, rising 47.3% year over year and 44.8% at constant currency. Double-digit growth in mitral and tricuspid procedures, increased adoption of PASCAL, the continued scaling of EVOQUE and the measured rollout of SAPIEN M3 drove the segment’s performance.
Surgical sales were $284 million, increasing 6.5% year over year and 5% at constant currency. Growth reflected continued adoption of RESILIA-based therapies, including INSPIRIS, MITRIS and KONECT. Edwards also received U.S. approval for ECLIPTIS and plans a measured rollout later in 2026.
Edwards’ Margins Reflect Earnings LeverageAdjusted gross margin was 77.6%, unchanged from the year-ago quarter. Foreign exchange created a 70 basis points (bps) headwind, which was offset by lower manufacturing expenses. Selling, general and administrative (SG&A) expenses increased to $561 million from $502 million, while research and development (R&D) expenses rose to $279 million from $276 million.
Adjusted operating income jumped 20.8% year over year to $522.7 million. The adjusted operating margin expanded 180 bps to 30%, supported by strong revenue growth and the planned timing of strategic investments in R&D and SG&A.
Edwards Maintains Financial FlexibilityAs of June 30, 2026, the company had approximately $2.90 billion in cash and cash equivalents. Total debt was about $600 million, leaving Edwards with substantial liquidity to support organic investment, manufacturing expansion and external opportunities in structural heart therapies.
The company also had roughly $1.50 billion remaining under its share-repurchase authorization. Management continues to prioritize growth investments before opportunistic capital returns.
EW Raises Sales Outlook and Reaffirms Earnings ViewEdwards increased its 2026 constant-currency sales growth guidance to 10-11% from the earlier 9-11%. Breaking it down, TAVR growth guidance was raised to 8-9% from 7-9%, while the TMTT sales outlook increased to $760-$780 million from $740-$780 million. Surgical sales are still expected to grow at a mid-single-digit rate.
Overall, EW now expects total sales of $6.60-$6.90 billion at current exchange rates. The Zacks Consensus Estimate for the same currently stands at $6.74 billion.
The company reaffirmed adjusted earnings guidance of $2.95-$3.05 per share despite expecting its tax rate to be at the high end of the prior 16-19% range. The Zacks Consensus Estimate for the metric is pegged at $3.00 at present.
For the third quarter of 2026, Edwards expects revenues of $1.63-$1.71 billion and adjusted earnings of 71-77 cents per share. The consensus mark for third-quarter revenues and earnings per share (EPS) is projected at $1.69 billion and 74 cents, respectively.
Our TakeEdwards exited the second quarter of 2026 with both earnings and revenues beating estimates. Performance reflected the strength of its comprehensive portfolio and agile execution, with growth supported by therapies across TAVR, mitral, tricuspid and surgical, as well as favorable contributions from each of the regions.
Within TAVR, Edwards’ competitive position in the United States is supported by continued adoption of its SAPIEN 3 Ultra RESILIA platform. TMTT benefited from the ongoing strong uptake of the PASCAL system. The expansion of adjusted operating margin in the quarter is also encouraging.
EW’s Zacks Rank and Key PicksEdwards currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Danaher (DHR - Free Report) and Elevance Health (ELV - Free Report) .
Intuitive Surgical, carrying a Zacks Rank #2 (Buy), reported second-quarter 2026 adjusted EPS of $2.80, which surpassed the Zacks Consensus Estimate by 12.9%. Revenues of $2.89 billion beat the Zacks Consensus Estimate by 3.1%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ISRG has an earnings yield of 3.1% compared to the industry’s negative 3% yield. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 16.53%.
Danaher, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $1.94, exceeding the Zacks Consensus Estimate by 5.44%. Revenues of $6.27 billion topped the Zacks Consensus Estimate by 2.88%.
DHR has an earnings yield of 4.7% compared with the industry’s 4.1% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 5.65%.
Elevance Health, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $7.45, exceeding the Zacks Consensus Estimate by 20.6%. Revenues of $49.8 billion outperformed the consensus mark by 0.8%.
ELV has an earnings yield of 6.9% compared to the industry’s 4.1% yield. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 5.65%.
Total Sales: $1.74 billion, a 12.5% increase year-over-year.Adjusted EPS: $0.78 for the quarter.TAVR Sales: $1.3 billion, a 10.5% increase over the prior year.
Edwards Lifesciences (EW - Free Report) reported $1.74 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 13.6%. EPS of $0.78 for the same period compares to $0.67 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $1.7 billion, representing a surprise of +2.45%. The company delivered an EPS surprise of +6.85%, with the consensus EPS estimate being $0.73.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Edwards Lifesciences performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Net Sales by Product Group- Transcatheter Mitral and Tricuspid Therapies: $198.6 million versus the four-analyst average estimate of $187.63 million. The reported number represents a year-over-year change of +47.7%.Net Sales by Product Group- Surgical Structural Heart: $284.1 million compared to the $277.73 million average estimate based on four analysts. The reported number represents a change of +6.5% year over year.Net Sales by Product Group- Transcatheter Aortic Valve Replacement: $1.26 billion versus the four-analyst average estimate of $1.23 billion. The reported number represents a year-over-year change of +11.3%.View all Key Company Metrics for Edwards Lifesciences here>>>
Shares of Edwards Lifesciences have returned -5.9% over the past month versus the Zacks S&P 500 composite's +0.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBHEdwards Lifesciences NYSE: EW reported stronger-than-expected second-quarter 2026 results, with management pointing to broad growth across transcatheter aortic valve replacement, transcatheter mitral and tricuspid therapies, and surgical products.
Chief Executive Officer Bernard Zovighian said the company delivered second-quarter sales growth of 12.5%, supported by “multiple therapies across TAVR, mitral, tricuspid, and surgical,” as well as contributions from each region. Total sales were $1.74 billion, and adjusted earnings per share were $0.78, according to Chief Financial Officer Doretta Mistras.
Get Edwards Lifesciences alerts:
Beyond Biotech—3 Healthcare Stocks for Growth-Minded InvestorsBased on the quarter’s performance, Edwards raised its full-year 2026 sales growth outlook for the total company, TAVR and TMTT while reaffirming its adjusted EPS guidance. The company now expects total company sales growth of 10% to 11%, up from 9% to 11%. It expects total company sales of $6.6 billion to $6.9 billion at current exchange rates. Adjusted EPS guidance remains $2.95 to $3.05.
TAVR Sales Beat Expectations Edwards reported global TAVR sales of $1.3 billion in the second quarter, up 10.5% from the prior year. Zovighian said the performance was stronger than expected and benefited from sustained clinical momentum, data supporting more proactive management of severe aortic stenosis, and continued adoption of the company’s SAPIEN platform.
3 Healthcare Pathbreakers With Long-Term TailwindsHe said TAVR growth rates were similar in the U.S. and outside the U.S. Average selling prices were stable globally. Growth also benefited from the exit of a competitor in the second quarter of 2025 and long-term durability data for SAPIEN, according to management.
Edwards raised its full-year TAVR sales growth guidance to 8% to 9%, from 7% to 9%. The company now expects TAVR sales of $4.75 billion to $5 billion at current exchange rates.
Zovighian said recent clinical presentations at the New York Valves Conference included a seven-year subanalysis supporting SAPIEN valve performance and durability, as well as a five-year analysis from the EARLY TAVR trial that added to evidence for treating aortic stenosis earlier in the disease pathway. He also said the first patients have been treated with the updated SAPIEN X4-S platform.
TMTT Growth Driven by Multiple Products Edwards’ transcatheter mitral and tricuspid therapies generated second-quarter sales of $195.9 million, up 44.8% year over year. Zovighian said PASCAL, EVOQUE and SAPIEN M3 all exceeded expectations in the quarter.
The company raised its full-year TMTT sales guidance to $760 million to $780 million, from $740 million to $780 million. Zovighian said the portfolio supports Edwards’ target of reaching $2 billion in TMTT revenue in 2030.
Management said PASCAL adoption continues to increase, citing physician interest in its design and clinical outcomes. Edwards expects next-generation PASCAL technology with Capture Clarity for mitral and tricuspid patients in the U.S. and Europe to be approved in the fourth quarter. The company also expects results from the Class II TR trial to be presented at TCT and plans a U.S. launch of PASCAL for tricuspid patients in the fourth quarter.
EVOQUE continues to scale in the U.S. and Europe, with Edwards expanding into new centers, increasing utilization at existing centers and working to streamline patient screening. Daveen Chopra, corporate vice president with responsibility for TMTT, surgical and IHFM, said EVOQUE is the second-largest TMTT platform by revenue after PASCAL and is “growing very quickly.”
For SAPIEN M3, Zovighian said early experience has validated the need for mitral replacement options for patients not well suited for mitral repair or surgery. Edwards received CE Mark for SAPIEN M3 RESILIA and broadened its indication for SAPIEN M3 and SAPIEN M3 RESILIA to include patients with mitral annular calcification.
Surgical Sales Rise 5% In surgical products, second-quarter global sales were $284 million, up 5% from the prior year. Zovighian said growth was driven by continued adoption of RESILIA-based therapies, including INSPIRIS, MITRIS and KONECT.
He also highlighted 10-year data from the COMMENCE trial presented at the AATS conference, saying the results showed favorable freedom from structural valve deterioration and a low rate of reoperation related to structural valve deterioration. Edwards also received U.S. approval for ECLIPTIS, its surgical left atrial appendage technology, and plans a measured rollout later this year.
The company continues to expect mid-single-digit sales growth in surgical in 2026.
Margins, Tax Rate and Third-Quarter Outlook Mistras said adjusted gross profit margin was 77.6% in the second quarter, flat from a year earlier, as foreign exchange headwinds were offset by lower manufacturing expenses. Foreign exchange reduced gross margin by 70 basis points compared with the prior year. The company now expects gross margin to be at the lower end of its full-year 78% to 79% guidance.
Second-quarter SG&A expense was $561 million, or 32% of sales, compared with $502 million a year earlier. R&D expense was $279 million, or 16% of sales, compared with $276 million, or 18% of sales, in the prior-year period. Edwards continues to expect R&D to be approximately 17% of sales in 2026.
Adjusted operating margin was 30% in the second quarter. Mistras said Edwards continues to expect full-year operating margin at the high end of its original 28% to 29% guidance, representing approximately 150 basis points of constant-currency operating margin expansion.
The company now expects its 2026 effective tax rate, excluding special items, to be at the high end of its prior 16% to 19% range, due to Pillar Two tax impacts and changes to California law limiting the use of R&D credits. GAAP EPS for the quarter was $0.42, primarily affected by the California R&D tax credit impact.
For the third quarter, Edwards projected sales of $1.63 billion to $1.71 billion and adjusted EPS of $0.71 to $0.77. Mistras said underlying growth in the third quarter will be “artificially lower” than first-half performance because the company faces a higher comparison from 2025, when seasonality had an unusually low impact.
Management Discusses NCD, PROGRESS Trial and Long-Term Growth During the question-and-answer session, analysts asked about TAVR growth drivers, the pending U.S. national coverage determination for TAVR, and the PROGRESS trial in moderate aortic stenosis.
Dan Lippis, Edwards’ global leader of TAVR, said the company is encouraged by the draft CMS policy and expects a final policy memo in September. He said potential benefits include a pathway for coverage of asymptomatic indications, recognition of symptomatic severe aortic stenosis as reasonable and necessary for Medicare beneficiaries without coverage with evidence development, and modernization of the policy to support heart teams in providing timely access to care.
On PROGRESS, Zovighian said Edwards separated the baseline characteristics presentation from the full results presentation to give physicians more time to understand the patient population. Lippis said the trial studies moderate aortic stenosis patients with at least one at-risk feature and emphasized that it is “not a heart failure trial.” Results are expected to be presented at TCT later this year.
Zovighian said the company expects minimal impact from PROGRESS in 2026 and reiterated that Edwards’ long-term TAVR outlook remains mid- to high-single-digit growth. He said the company remains confident in its target of approximately 10% average annual total company sales growth over the long term, alongside operating margin expansion.
About Edwards Lifesciences (NYSE:EW)Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Edwards Lifesciences Right Now?Before you consider Edwards Lifesciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edwards Lifesciences wasn't on the list.
While Edwards Lifesciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2026. Highlights Q2 sales grew 13.6% to $1.74 billion1, constant currency2 sales grew 12.5% Q2 TAVR sales grew 11.3% to $1.26 billion1; constant currency2 sales grew 10.5% Q2 TMTT sales were $195.9 million1,3, driven by portfolio of repair and replacement therapies Q2 EPS of $0.421; adjusted2 EPS of $0.781 Recent clinical data at New York Valves reinforce best-in-clas.
Information in Investor’s Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or performance. Authors/presenters may own the stocks they discuss. We make no representations or warranties regarding the advisability of investing in any particular securities or utilizing any specific investment strategies. Information is subject to change without notice. For information on use of our services, please see our Terms of Use.
*Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet.
IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC.
The medical-technology company said it now expects sales of $6.6 billion to $6.9 billion for the full year, raising the bottom end of its prior range of $6.5 billion to $6.9 billion.
CompaniesJuly 23 (Reuters) - Edwards Lifesciences (EW.N), opens new tab beat analysts' estimates for second-quarter profit and revenue on Thursday, helped by strong demand for its artificial heart valves used in complex cardiac procedures, sending its shares up nearly 7% in extended trading.
Medical technology firms are seeing increased demand for surgical and procedural devices as population ages and healthcare needs grow.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
Here are some details:
Sales of Edwards' transcatheter aortic valve replacement device (TAVR) rose 11.3% over the year earlier to $1.26 billion during the quarter. Analysts on average estimated $1.23 billion, according to data compiled by LSEG.
TAVR is used to treat severe aortic stenosis, a condition where the aortic valve narrows and restricts blood flow from the heart.
Edwards raised the lower end of 2026 sales growth forecast for TAVR devices to 8% from 7% earlier, while keeping the upper end intact at 9%.
The company maintained annual adjusted profit expectations in the range of $2.95 to $3.05 per share.
The California-based company reported quarterly revenue of $1.74 billion, while analysts estimated $1.70 billion.
On an adjusted basis, Edwards earned 78 cents per share, compared with the estimate of 74 cents.
Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Shilpi Majumdar
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Andra AP fonden boosted its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 283.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 114,969 shares of the medical research company’s stock after acquiring an additional 84,969 shares during the quarter. Andra AP fonden’s holdings in Edwards Lifesciences were worth $9,207,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. MV Capital Management Inc. purchased a new stake in Edwards Lifesciences during the fourth quarter worth about $26,000. Hanson & Doremus Investment Management acquired a new position in shares of Edwards Lifesciences in the first quarter valued at approximately $25,000. Kemnay Advisory Services Inc. purchased a new stake in Edwards Lifesciences during the 4th quarter worth approximately $27,000. JPL Wealth Management LLC acquired a new stake in Edwards Lifesciences during the 3rd quarter worth approximately $25,000. Finally, Hilton Head Capital Partners LLC purchased a new position in Edwards Lifesciences in the 4th quarter valued at approximately $28,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.
Edwards Lifesciences Trading Down 0.7% NYSE EW opened at $84.41 on Wednesday. The firm’s fifty day moving average price is $87.60 and its 200 day moving average price is $83.91. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The company has a market capitalization of $48.61 billion, a price-to-earnings ratio of 44.90, a price-to-earnings-growth ratio of 2.13 and a beta of 0.86.
Edwards Lifesciences (NYSE:EW – Get Free Report) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The company had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. During the same period last year, the firm posted $0.64 EPS. Edwards Lifesciences’s revenue for the quarter was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, sell-side analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.
Analysts Set New Price Targets EW has been the topic of several analyst reports. TD Cowen reiterated a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday. Royal Bank Of Canada upped their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. BTIG Research raised their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Wall Street Zen downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Finally, Canaccord Genuity Group set a $85.00 price target on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average target price of $98.95.
Get Our Latest Stock Analysis on EW
Insider Buying and Selling at Edwards Lifesciences In related news, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the sale, the vice president directly owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. This represents a 19.01% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the firm’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $91.70, for a total value of $56,762.30. Following the transaction, the vice president directly owned 40,034 shares of the company’s stock, valued at $3,671,117.80. The trade was a 1.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 45,577 shares of company stock valued at $3,855,527. 0.31% of the stock is owned by corporate insiders.
Edwards Lifesciences Company Profile (Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Further Reading Five stocks we like better than Edwards Lifesciences Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINECalifornia Public Employees Retirement System Buys 44,533 Shares of Entegris, Inc. $ENTG
NEXT HEADLINE »California Public Employees Retirement System Sells 7,774 Shares of Global Payments Inc. $GPN
Key Takeaways EW is set to report Q2 2026 results on July 23, with revenues expected to rise 10.9% year over year.Edwards' TAVR growth may be aided by SAPIEN demand, clinical evidence and European guideline support.Edwards' TMTT and Surgical may have benefited from EVOQUE, SAPIEN M3, PASCAL and RESILIA therapy demand. Edwards Lifesciences Corp. (EW - Free Report) is scheduled to report second-quarter 2026 results on July 23, after the market closes.
In the last reported quarter, the company’s adjusted earnings per share (EPS) of 78 cents beat the Zacks Consensus Estimate by 4%. Its earnings topped estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 4.79%.
Edwards' Q2 EstimatesThe Zacks Consensus Estimate for the company’s second-quarter 2026 revenues is pegged at $1.70 billion, suggesting 10.9% growth from the year-ago reported figure.
The Zacks Consensus Estimate for second-quarter 2026 net earnings of 73 cents per share indicates a 9% increase from the year-ago reported figure. The estimate has remained unchanged in the past 60 days.
Factors Likely to Influence EW’s Q2 ResultsTranscatheter Aortic Valve Replacement (TAVR)In the second quarter of 2026, the TAVR segment is likely to have maintained its momentum, aided by procedural growth amid a heightened clinical focus on proactive disease management of severe aortic stenosis. Long-term clinical evidence supporting the SAPIEN platform’s durability and valve performance may have been a key driver.
Edwards may have continued to see strong sales of the SAPIEN 3 Ultra RESILIA valve across the United States and international markets, including Japan. In Europe, continued commercial execution and sustained physician demand for the SAPIEN platform are expected to have supported performance. The company may have continued to benefit from the exit of a competitor in the prior year.
Updated guidelines from the European Society of Cardiology and the European Association for Cardiothoracic Surgery, endorsing the role of TAVR for a broader patient population, may have positively influenced the segment’s performance.
The Zacks Consensus Estimate expects TAVR revenues to grow 9.1% year over year in the second quarter.
Transcatheter Mitral and Tricuspid Therapies (TMTT)Within TMTT, Edwards’ ongoing strength in the portfolio of repair and replacement therapies to treat mitral and tricuspid diseases is expected to have resulted in solid top-line growth. The EVOQUE tricuspid valve replacement system is likely to have continued to gain traction in both the United States and Europe.
Last year, the FDA approval of the SAPIEN M3 mitral valve replacement system marked a major milestone as the first transcatheter therapy utilizing a transseptal approach. Edwards’ early commercial experience has reflected the need for this mitral replacement solution for patients for whom mitral TEER is not an appropriate treatment option.
Favorable physician feedback on patient outcomes and procedural experience is likely to have continued to support the system’s adoption in the second quarter. Demand for the PASCAL transcatheter edge-to-edge repair system may have continued to expand, driven by physician interest in its differentiated design and clinical outcomes, as well as the significant unmet need among these patients.
The Zacks Consensus Estimate expects TMTT revenues to grow 39.3% year over year in second-quarter 2026.
Surgical Structural HeartThe segment’s second-quarter performance is likely to have benefited from the continued demand for Edwards’ RESILIA therapies. The global adoption of the INSPIRIS aortic valve is expected to have remained strong, while the KONECT tissue valved conduit is likely to have continued to gain traction following its European launch. The rollout of the MITRIS valve across more international markets may have supported growth in surgical mitral valve replacement procedures.
With Edwards maintaining its outlook for mid-single-digit Surgical sales growth in 2026, the second quarter is likely to have seen continued progress toward that target.
The Zacks Consensus Estimate anticipates Surgical revenues to grow 4.1% year over year.
Earnings Whispers for EdwardsPer our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is not the case here, as you can see below:
Earnings ESP: Edwards has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
MedTech PicksHere are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:
Labcorp (LH - Free Report) has an Earnings ESP of +0.71% and a Zacks Rank #2. The company is slated to release second-quarter 2026 results on July 30.
LH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.31%. The Zacks Consensus Estimate expects the company’s second-quarter EPS to increase 10.1% from the year-ago quarter’s figure.
Henry Schein (HSIC - Free Report) has an Earnings ESP of +0.41% and a Zacks Rank #2. The company is expected to release second-quarter 2026 results soon.
HSIC’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.74%. The Zacks Consensus Estimate for the company’s second-quarter EPS calls for a rise of 10.9% from the year-ago quarter’s figure.
Alcon (ALC - Free Report) has an Earnings ESP of +3.13% and a Zacks Rank #2. The company is slated to release second-quarter 2026 results on Aug. 10.
ALC’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.66%. The Zacks Consensus Estimate anticipates the company’s second-quarter EPS to increase 1.3% from the year-ago quarter’s figure.
Boston Common Asset Management LLC increased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 4.5% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 156,297 shares of the medical research company’s stock after purchasing an additional 6,744 shares during the quarter. Boston Common Asset Management LLC’s holdings in Edwards Lifesciences were worth $12,516,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Hanson & Doremus Investment Management bought a new stake in Edwards Lifesciences during the 1st quarter worth about $25,000. JPL Wealth Management LLC bought a new position in shares of Edwards Lifesciences in the 3rd quarter valued at about $25,000. MV Capital Management Inc. bought a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $26,000. Kemnay Advisory Services Inc. acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $27,000. Finally, Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $28,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at Edwards Lifesciences In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the company’s stock in a transaction on Friday, July 10th. The shares were sold at an average price of $91.70, for a total value of $56,762.30. Following the transaction, the vice president directly owned 40,034 shares in the company, valued at $3,671,117.80. The trade was a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the transaction, the vice president directly owned 98,611 shares in the company, valued at $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 45,577 shares of company stock valued at $3,855,527 in the last quarter. 0.31% of the stock is currently owned by insiders.
Analyst Ratings Changes EW has been the subject of a number of analyst reports. BTIG Research raised their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. Truist Financial upped their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a research note on Thursday. Wall Street Zen cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. TD Cowen restated a “buy” rating and set a $104.00 target price (up from $97.00) on shares of Edwards Lifesciences in a report on Tuesday, June 2nd. Finally, Citigroup upped their price target on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average target price of $98.95.
Read Our Latest Report on Edwards Lifesciences
Edwards Lifesciences Price Performance NYSE:EW opened at $85.72 on Monday. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $96.29. The firm has a market capitalization of $49.36 billion, a price-to-earnings ratio of 45.60, a P/E/G ratio of 2.15 and a beta of 0.86. The stock’s 50 day moving average price is $87.34 and its two-hundred day moving average price is $83.92. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06.
Edwards Lifesciences (NYSE:EW – Get Free Report) last issued its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.73 by $0.05. The company had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The firm’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.
About Edwards Lifesciences (Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Featured Articles Five stocks we like better than Edwards Lifesciences Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand Rises 3 Aerospace Suppliers That Could Benefit as Aircraft Makers Face Bottlenecks Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEBoston Common Asset Management LLC Has $10.77 Million Position in Gilead Sciences, Inc. $GILD
NEXT HEADLINE »Cantillon Capital Management LLC Sells 1,451,818 Shares of Applied Materials, Inc. $AMAT
Diversify Wealth Management LLC reduced its position in shares of Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 91.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,910 shares of the medical research company’s stock after selling 42,906 shares during the period. Diversify Wealth Management LLC’s holdings in Edwards Lifesciences were worth $318,000 at the end of the most recent quarter.
Other large investors have also modified their holdings of the company. MV Capital Management Inc. acquired a new stake in shares of Edwards Lifesciences in the 4th quarter worth $26,000. Hanson & Doremus Investment Management purchased a new position in shares of Edwards Lifesciences during the 1st quarter worth $25,000. Kemnay Advisory Services Inc. acquired a new position in shares of Edwards Lifesciences during the 4th quarter valued at about $27,000. JPL Wealth Management LLC acquired a new position in shares of Edwards Lifesciences during the 3rd quarter valued at about $25,000. Finally, Hilton Head Capital Partners LLC purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $28,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.
Insiders Place Their Bets In related news, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the transaction, the vice president owned 98,611 shares of the company’s stock, valued at $8,521,962.62. This trade represents a 19.01% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 45,577 shares of company stock worth $3,855,527 in the last quarter. 0.31% of the stock is owned by company insiders.
Edwards Lifesciences Stock Performance NYSE EW opened at $85.72 on Friday. The company has a market cap of $49.36 billion, a P/E ratio of 45.60, a P/E/G ratio of 2.15 and a beta of 0.86. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The stock has a 50-day moving average of $87.34 and a two-hundred day moving average of $83.94. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $96.29.
Edwards Lifesciences (NYSE:EW – Get Free Report) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.73 by $0.05. The business had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current year.
Analyst Upgrades and Downgrades EW has been the topic of a number of analyst reports. Wall Street Zen downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Citigroup increased their price target on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. BTIG Research raised their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Mizuho upped their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $98.95.
Check Out Our Latest Stock Report on Edwards Lifesciences
Edwards Lifesciences Profile (Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Read More Five stocks we like better than Edwards Lifesciences Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs? The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Why Intuitive Surgical’s Strong Quarter Still Spooked Investors Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEFifth Third Bancorp Increases Stock Position in Powell Industries, Inc. $POWL
NEXT HEADLINE »ANB Bank Acquires Shares of 10,345 Netflix, Inc. $NFLX
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2026 after the market closes on Thursday July 23, and will host a conference call at 5:00 p.m. ET that day to discuss those results.
To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com.
About Edwards Lifesciences
Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube.
Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Edwards Lifesciences Corporation (NYSE: EW) breached their fiduciary duties to shareholders.
If you currently own Edwards stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].
Why Your Participation Matters:
Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com
NEW YORK--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new data presented at New York Valves 2026, the annual conference organized by the Cardiovascular Research Foundation, which reinforce the company's leadership in advancing high-quality scientific evidence and innovating for patients. These new data – spanning aortic, mitral and tricuspid therapies – provide further understanding of the complexity of structural heart disease and the need for innovative treatment options.
Ahead of the planned full clinical presentation at TCT later this year, the baseline characteristics of the PROGRESS trial presented today provide new insights into the heterogeneous nature of moderate aortic stenosis (AS) patients. Research has shown that approximately half of moderate AS patients present with at least one at-risk feature, which includes symptoms, progressive cardiac damage, declining health and elevated risk of hospitalization. The PROGRESS trial is designed to evaluate whether patients with moderate AS and at least one risk factor may benefit from transcatheter aortic valve replacement (TAVR) earlier than current guidelines, which recommend clinical surveillance with echocardiographic follow-up every 1-2 years. Details of the PROGRESS trial design were recently published in the American Heart Journal and baseline characteristics of the PROGRESS trial are listed below:
More than 95% were symptomatic More than 70% had 2 or more at-risk features More than 90% had a normal left ventricular function Mean age was 78 ± 6 years Mean KCCQ score was 64 ± 24 Broad surgical risk distribution (46% low risk) Additional late-breaking clinical science presentations strengthen the evidence base for the SAPIEN 3 platform, including seven-year benchmark durability data from the PARTNER 3 trial, simultaneously published in JAMA Cardiology. Also presented were new findings from the EARLY TAVR trial, reinforcing the shift toward proactive disease management and providing continued long-term reassurance for physicians and patients. These data on Edwards’ SAPIEN platform underscore the benchmark valve performance and differentiated long-term durability of the therapy.
“Edwards remains focused on addressing the significant unmet needs of the many structural heart patients who remain untreated today,” said Bernard Zovighian, Edwards’ CEO. “Our expanding evidence base reflects Edwards’ clear and sustained commitment to advancing care through partnership with the physician community. From building a deeper understanding of the moderate AS population and advancing evidence about asymptomatic patients to demonstrating distinguished SAPIEN platform durability and strategies for lifetime disease management, we are strengthening confidence in long-term outcomes and increasing access for patients worldwide.”
Also at the meeting, new data highlighted clinical trial and real-world outcomes across Edwards’ mitral and tricuspid portfolio. Data from more than 4,500 patients treated with the PASCAL system in the STS/ACC Transcatheter Valve Therapy Registry helps highlight the sustained safety and effectiveness of the technology for patients with mitral regurgitation (MR). One-year data from the ENCIRCLE trial Mitral Annular Calcification (MAC) Registry support the safety, effectiveness and quality of life improvements with SAPIEN M3, the first and only transcatheter transseptal mitral valve replacement system, in patients with symptomatic valve dysfunction associated with MAC who are deemed unsuitable for surgery or TEER therapy by a heart team.
Zovighian added, “Together, our differentiated technology and world-class evidence reflect Edwards’ leadership in elevating the standard of care for structural heart patients and improving outcomes across the care continuum.”
About Edwards Lifesciences
Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube.
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, but are not limited to, statements made by Mr. Zovighian and statements regarding the benchmark performance and differentiated long-term durability of Edwards’ SAPIEN platform, elevating the standard of care, our leadership in advancing our growing body of high-quality scientific and clinical evidence, long-term reassurance for physicians and patients, our commitment to advance care through partnerships with the physician community, strengthen confidence in long-term outcomes and expanding access for patients, innovating for patients with structural heart disease, the safety and effectiveness and quality of life improvements of our products, and improving outcomes across the care continuum, and other statements that are not historical facts. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Investors are cautioned not to unduly rely on such forward-looking statements.
Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors as detailed in the company's filings with the Securities and Exchange Commission. These filings, along with important safety information about our products, may be found at Edwards.com.
Edwards, Edwards Lifesciences, the stylized E logo, EARLY TAVR, ENCIRCLE, PARTNER, PARTNER 3, PASCAL, PROGRESS, SAPIEN, SAPIEN 3 and SAPIEN M3 are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.
New SWH1530VP delivers high-speed Data Plane and Control Plane networking across physically separated enclaves while accelerating integration of SOSA™ and CMOSS-aligned mission systems
EL SEGUNDO, Calif.--(BUSINESS WIRE)--Pacific Defense today announced the launch of the SWH1530VP, a next-generation dual-enclave 100/40 Gigabit Ethernet switch engineered to provide secure, deterministic, and high-performance networking for modern Command, Control, Communications, Computers, Cyber, Intelligence, Surveillance, Reconnaissance (C5ISR), Electronic Warfare (EW), and edge computing applications. Aligned with SOSA™, CMOSS, and OpenVPX™ standards, the 3U VPX module combines advanced Layer 2/Layer 3 switching, precision timing, and physically separated network enclaves in a low Size, Weight, and Power (SWaP) solution optimized for deployment across air, land, and maritime platforms.
"SWH1530VP addresses a critical need for secure, high-performance networking in modern mission systems where multiple security domains, high-speed data movement, and precise timing must coexist within an open architecture framework," said Pedja Mitrovic.
Share Designed to address growing requirements for secure multi-domain mission systems, the SWH1530VP integrates independent Data Plane and Control Plane Ethernet switch fabrics capable of supporting up to 100 Gbps networking while maintaining physical separation between security enclaves. This architecture simplifies system integration and certification efforts while enabling high-bandwidth sensor processing, mission computing, communications, and electronic warfare applications within a common open architecture framework.
Built on leading-edge Ethernet switching technology from Marvell's Prestera® Aldrin2 and Ironman device families, the SWH1530VP delivers advanced standards-based networking capabilities including various Layer 2/Layer 3 switching protocols including static and dynamic routing, Quality of Service (QoS), VLAN support with tagging and port mirroring, multicast with IGMP snooping support, IEEE 1588 Precision Time Protocol (PTP), and link-layer security and enhanced authentication including integrated MACsec security acceleration. The platform is further designed to support future Time Sensitive Networking (TSN) capabilities through software enhancement, enabling deterministic networking for increasingly complex mission systems.
"The SWH1530VP addresses a critical need for secure, high-performance networking in modern mission systems where multiple security domains, high-speed data movement, and precise timing must coexist within an open architecture framework," said Pedja Mitrovic, VP of Modular Products at Pacific Defense. "By combining dual-enclave operation, 100 Gigabit networking, advanced security features, and SOSA/CMOSS alignment, the SWH1530VP enables system integrators to accelerate deployment of next-generation C5ISR, EW, and edge-computing capabilities while reducing integration risk and lifecycle costs."
The SWH1530VP is compliant with ANSI/VITA 48.2 VPX REDI conduction cooling and VITA 47 environmental standards, ensuring reliable operation in demanding military environments while supporting interoperability across a broad ecosystem of open systems hardware and software solutions for both commercial and defense applications.
Key Features of the SWH1530VP
3U VPX form factor aligned with CMOSS, SOSA™, and OpenVPX™ standards Dual independent Layer 2/Layer 3 Ethernet switch matrices for physically separated enclaves Up to 100 Gbps Ethernet connectivity with support for 100GBASE-KR4, 40GBASE-KR4, 10GBASE-KR, and 1000BASE-KX High-speed Data Plane and deterministic Control Plane networking with auto-negotiation support IEEE 1588 PTP Transparent Clock functionality for precision timing applications Integrated MACsec security acceleration and advanced authentication capabilities Future support for Time Sensitive Networking (TSN) through software updates For more information on the SWH1530VP, visit the product page here: SWH1530VP OpenVPX™ 100/40G Ethernet Switch | Pacific Defense
About Pacific Defense
Pacific Defense is purpose-built to drive the open-systems transformation required to unlock rapid innovation and the power of commercial technology. Specializing in C5ISR and Electronic Warfare (EW) solutions for mission-critical environments, Pacific Defense applies MOSA standards to deliver flexible, upgradeable technology that helps warfighters stay ahead of emerging threats. Learn more at www.pacific-defense.com and on LinkedIn.
On June 17, 2026, we present a DCF analysis for Edwards Lifesciences Corp EW . The company has shown a price performance of +1.2% over the past week, +8.8% over the past month, +3.9% year-to-date, and +18.4% over the past year. Here are some key points from our analysis:
DCF Earnings-based intrinsic value is $51.05, indicating a margin of safety of -73.5% compared to the current price of $88.58. DCF Free Cash Flow (FCF)-based intrinsic value is $21.50, suggesting a significantly overvalued status. GF Score™ of 97/100 indicates high reliability of the DCF inputs. What Is EW Worth? DCF Earnings-Based Model In our DCF earnings-based model, we assume a current EPS (TTM, excluding non-recurring items) of $2.70 and a 10-year earnings growth rate of 12.5%. The discount rate is calculated at 11%, based on the 10-Year Treasury Rate of 4.43% plus an equity risk premium of 6%. The terminal growth rate is set at 4% for years 11-20.
Parameter Value Current EPS (TTM, excl. non-recurring) $2.70 10-Year Growth Rate 12.5% 10-Year Treasury Rate 4.43% Discount Rate (ceil(Treasury) + 6%) 11% Terminal Growth Rate 4% Our two-stage model consists of a growth phase (Years 1-10) where EPS grows at 12.5% per year, discounted at 11%, and a terminal phase (Years 11-20) where growth slows to a 4% terminal rate, also discounted at 11%. Below is the calculation summary:
Stage Description Value Growth Stage (Years 1-10) EPS growing at 12.5%, discounted at 11% $29.09 Terminal Stage (Years 11-20) 4% terminal growth, discounted at 11% $21.96 Intrinsic Value Growth + Terminal $51.05 With the current price at $88.58, the intrinsic value of $51.05 indicates that the stock is modestly overvalued, with a margin of safety of -73.5%. It is important to note that GuruFocus uses EPS without non-recurring items because research shows stock prices correlate more closely with earnings than free cash flow. For further details, visit the EW DCF Calculator.
What Does the Free Cash Flow DCF Say? The free cash flow (FCF)-based intrinsic value for Edwards Lifesciences Corp is calculated at $21.50. When comparing this with the earnings-based intrinsic value of $51.05, the two models disagree significantly. The FCF model indicates that the stock is significantly overvalued, with a margin of safety of -312.0%.
How Does GF Value™ Compare to the DCF Models? The GF Value™ for Edwards Lifesciences Corp is $92.96, providing a third perspective on valuation. GF Value™ is GuruFocus' proprietary measure calculated from historical trading multiples, past business growth, and future performance estimates. While the DCF earnings model suggests modest overvaluation and the FCF model indicates significant overvaluation, the GF Value™ suggests that the stock is undervalued by 4.7%. This divergence among the three models highlights the complexity of valuation assessments. For more information, visit the GF Value™ page.
What Does EW's GF Score™ Tell Us? The GF Score™ ranks stocks from 0 to 100 based on five key aspects: Financial Strength, Profitability, Growth, Valuation, and Momentum. Stocks with higher GF Score™ values have been found to generate higher long-term returns (backtested 2006-2021). Below is the breakdown of Edwards Lifesciences Corp's GF Score™:
Metric Rating GF Score™ 97/100 Financial Strength 9/10 Profitability 9/10 Growth 10/10 Valuation 10/10 Momentum 7/10 The predictability rank is 1/5 stars, indicating that higher predictability means the DCF model is less reliable for this stock. For more insights, visit the EW stock page.
Key Assumptions and Limitations It is essential to recognize that DCF models are highly sensitive to growth rate and discount rate assumptions. Stocks with low predictability ratings, such as Edwards Lifesciences Corp, produce less reliable DCF estimates. The terminal growth rate of 4% is a simplifying assumption that may not reflect future economic conditions.
What This Means for Investors In synthesizing the three valuation models—DCF earnings, DCF FCF, and GF Value™—we find a consensus indicating that Edwards Lifesciences Corp is overvalued. The earnings-based model suggests modest overvaluation, while the FCF model indicates significant overvaluation. However, the GF Value™ suggests a slight undervaluation. Overall, the clear verdict is that the stock appears to be overvalued at its current price. For the full DCF analysis, visit the EW DCF Calculator. You can also explore the GF Value™ page, or use the GuruFocus Stock Screener to find undervalued predictable companies.
Frequently Asked Questions What is EW's intrinsic value based on DCF?
Answer: earnings-based $51.05, FCF-based $21.50
Is EW overvalued or undervalued?
Answer: Based on the DCF and GF Value™ consensus, EW is overvalued.
How reliable is the DCF model for EW?
Answer: The predictability rank is 1/5, indicating lower reliability for the DCF model.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
On Monday, the Centers for Medicare & Medicaid Services (CMS) proposed removing the coverage with evidence development (CED) requirement for Transcatheter Aortic Valve Replacement (TAVR) in patients with symptomatic severe aortic stenosis.
William Blair on Tuesday wrote, "…this is a positive outcome for Edwards and largely validates the thesis we laid out following the NCD opening in December."
CMS Proposes Changes To TAVR Coverage RequirementsAortic stenosis is a narrowing or stiffening of the heart's aortic valve. It restricts blood flow from the heart's main pumping chamber to the rest of the body.
The agency also proposed expanding TAVR coverage to patients with asymptomatic severe aortic stenosis under CED and updating coverage criteria for pre-procedure evaluations, intraoperative standards, and operator and hospital volume requirements.
Analyst Views CMS Proposal As Positive For Edwards LifesciencesCoverage with CED appears appropriate, given that asymptomatic severe aortic stenosis patients represent an early-stage treatment population, and continued data collection should benefit stakeholders across the healthcare system.
Expanded Coverage Could Support TAVR AdoptionWilliam Blair also noted that Edwards currently has the only FDA-approved TAVR device indicated for asymptomatic severe AS patients.
If coverage is included in the final NCD, it would provide the company with a meaningful competitive advantage.
Implementation of the NCD could catalyze TAVR adoption by simplifying the treatment pathway and enabling patients to access therapy sooner.
William Blair maintains the Outperform rating for the structural heart company.
EW Stock Price Activity: Edwards Lifesciences shares were up 3.74% at $88.65 at the time of publication on Tuesday, according to Benzinga Pro data.
Photo: Shutterstock
Market News and Data brought to you by Benzinga APIs
CompaniesApril 23 (Reuters) - Edwards Lifesciences (EW.N), opens new tab beat Wall Street first-quarter estimates on Thursday, driven by robust demand for its artificial valves used in complex cardiac procedures, sending its shares up over 4% in extended trading.
Medical technology firms are benefiting from aging populations that require more healthcare, leading to increased use of surgical and procedural devices.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
Sales of Edwards' transcatheter aortic valve replacement device (TAVR) rose 14.4% year-over-year to $1.2 billion in the quarter, compared to estimates of $1.15 billion, according to data compiled by LSEG.
TAVR is used to treat severe aortic stenosis, a condition where the aortic valve narrows and restricts blood flow from the heart.
The company now expects adjusted annual profit in the range of $2.95 to $3.05 per share, compared to its previous projection of $2.90 to $3.05 per share.
It raised its annual sales growth forecast to a range of 9% to 11%, up from a previously disclosed range of 8% to 10%.
The California-based company reported quarterly revenue of $1.65 billion, topping estimates of $1.6 billion.
On an adjusted basis, Edwards earned a profit of 78 cents per share, surpassing analysts' estimate of 73 cents per share.
Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Vijay Kishore
Our Standards: The Thomson Reuters Trust Principles., opens new tab
For the quarter ended March 2026, Edwards Lifesciences (EW - Free Report) reported revenue of $1.65 billion, up 16.7% over the same period last year. EPS came in at $0.78, compared to $0.64 in the year-ago quarter.
The reported revenue represents no surprise over the Zacks Consensus Estimate of $0 million. With the consensus EPS estimate being $0.67, the EPS surprise was +16.42%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Edwards Lifesciences performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Net Sales by Product Group- Transcatheter Mitral and Tricuspid Therapies: $175.1 million versus $161 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +52% change.Net Sales by Product Group- Surgical Structural Heart: $276.2 million versus the five-analyst average estimate of $267.25 million. The reported number represents a year-over-year change of +10.1%.Net Sales by Product Group- Transcatheter Aortic Valve Replacement: $1.2 billion compared to the $1.17 billion average estimate based on five analysts. The reported number represents a change of +14.4% year over year.View all Key Company Metrics for Edwards Lifesciences here>>>
Shares of Edwards Lifesciences have returned -1.4% over the past month versus the Zacks S&P 500 composite's +9.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
• Edwards Lifesciences stock is surging to new heights today. What’s behind EW gains?
Edwards Lifesciences Q1 Earnings Drive Stock MoveThe heart devices company on Thursday reported quarterly adjusted earnings of 78 cents, beating the consensus of 73 cents. Sales reached $1.65 billion, beating the consensus of $1.59 billion.
Edwards Lifesciences announced a 16.7% year-over-year (+12.7% at constant currency) increase in sales for the first quarter, driven by robust demand for its heart valve therapies.
The company also noted significant growth in its transcatheter mitral and tricuspid procedures, further solidifying its position in the market.
Valve Therapies and TAVR Drive GrowthThe company reported Transcatheter Aortic Valve Replacement (TAVR) sales of $1.2 billion, up 14.4% (+11%). SAPIEN growth in the U.S. was healthy, and it was even faster outside of the U.S.
Edwards’ global competitive position in the first quarter increased slightly year-over-year, mainly due to the exit of a competitor in Europe.
Transcatheter Mitral and Tricuspid Therapies (TMTT) sales of $173 million were driven by the company’s portfolio of repair and replacement therapies to treat mitral and tricuspid diseases.
Globally, mitral and tricuspid procedures grew in the estimated double digits, with Edwards’ sales growing at a higher rate.
Guidance UpdatedEdwards Lifesciences raised its fiscal 2026 adjusted earnings per share from $2.90-$3.05 to $2.95-$3.05 compared to the consensus of $2.93.
It also widened 2026 sales guidance from $6.55 billion-$6.67 billion to $6.50 billion-$6.90 billion compared to the consensus estimate of $6.68 billion.
The company expects second-quarter adjusted earnings of 70 cents -76 cents compared to the consensus of 75 cents.
It forecasts sales between $1.66 billion and $1.74 billion compared to the consensus of $1.68 billion.
Analyst Consensus & Recent Actions: The stock carries a Buy Rating with a consensus price target of $99.75. Recent analyst moves include:
Evercore ISI Group: Outperform (Raises target to $93 on April 24) Baird: Neutral (Raises target to $87 on April 24) Cannacord: Hold (Lowers target to $85 on April 13) How Edwards Lifesciences Ranks On Growth and MomentumBelow is the Benzinga Edge scorecard for Edwards Lifesciences, highlighting its strengths and weaknesses compared to the broader market:
Value: 49.28 — The stock is trading at a moderate valuation relative to peers. Growth: 78.39 — Indicates strong growth potential. Quality: 56.2 — Reflects a solid balance sheet and operational efficiency. Momentum: 34.25 — Suggests weaker performance in recent trading. The Verdict: Edwards Lifesciences’ Benzinga Edge signal reveals a growth-heavy profile, supported by strong sales growth in its innovative therapies. However, the momentum score indicates the stock may be facing some challenges in maintaining upward price movement.
EW Stock Price Activity: Edwards Lifesciences shares were up 4.58% at $83.37 at publication on Friday, according to Benzinga Pro data.
Image via Shutterstock
Market News and Data brought to you by Benzinga APIs
Key Takeaways EW beat Q1 EPS by 16.4% with 21.9% growth; revenues rose 17% to $1.65B, matching estimates. Edwards Lifesciences saw TAVR sales rise 14.4% and TMTT jump 51.9% on strong therapy adoption.EW raised 2026 sales growth guidance to 9-11% and EPS view to $2.95-$3.05, signaling confidence ahead. Edwards Lifesciences Corporation (EW - Free Report) reported first-quarter 2026 adjusted earnings per share (EPS) of 78 cents, which surpassed the Zacks Consensus Estimate by 16.4%. The figure increased 21.9% on a year-over-year basis.
One-time adjustments primarily include certain litigation and restructuring expenses. GAAP EPS from continuing operations was 66 cents compared with 62 cents in the year-ago period.
Edwards’ Q1 RevenuesSales totaled $1.65 billion, up 17% year over year. The metric was in line with the Zacks Consensus Estimate.
Following the earnings announcement, EW stock rose 2.3% in the aftermarket trading yesterday.
EW’s Q1 Sales by SegmentsTranscatheter Aortic Valve Replacement (“TAVR”)
Global sales in the product group amounted to $1.20 billion, up 14.4% year over year or 11% at constant currency (CER). The performance reflected clinicians’ heightened focus on SAPIEN therapy and proactive disease management of patients suffering from severe aortic stenosis.
Transcatheter Mitral and Tricuspid Therapies (“TMTT”)
Sales totaled $175.1 million, up 51.9% from the prior-year figure on a reported basis. The global adoption of PASCAL and EVOQUE contributed to the overall growth.
Surgical Structural Heart
Global Surgical sales from continuing operations amounted to $276.2 million, up 10.1% year over year or 5.9% at CER. Growth was driven by continued adoption of RESILIA therapies that offer extended durability.
Edwards’ Q1 Margin PerformanceThe gross profit was $1.29 billion, up 15.7% year over year. The gross margin contracted 64 basis points (bps) to 78% due to a 20.2% increase in the cost of sales.
SG&A expenses rose 12.1% year over year to $522.2 million. R&D expenditures amounted to $263.3 million, up 3.4% year over year.
The operating income increased 28.1% year over year to $500.5 million. The operating margin expanded 269 bps to 30.4%.
EW’s Cash PositionThe company exited the first quarter of 2026 with cash and cash equivalents of $2.40 billion compared with $3.00 billion in the fourth quarter of 2025. Total debt was roughly $600 million, in line with the 2025 figure.
Edwards Lifesciences Corporation Price, Consensus and EPS SurpriseEdwards’ 2026 GuidanceFor 2026, the company has guided sales growth rate between 9% and 11% (up from 8% and 10%). The Zacks Consensus Estimate for sales is pegged at $6.66 billion, suggesting a 9.8% increase from the 2025 level.
Adjusted EPS is now projected to be in the $2.95-$3.05 range (previously $2.90-$3.05). The Zacks Consensus Estimate is pegged at $2.96.
For the second quarter of 2026, EW projects total sales in the band of $1.66-$1.74 billion and adjusted EPS in the 70-76 cents range. The Zacks Consensus Estimate for second-quarter sales and EPS is pinned at $1.68 billion and 75 cents, respectively.
Our TakeEdwards Lifesciences’ first-quarter earnings beat estimates but revenues matched the same. Within TAVR, the company saw intentional and urgent treatment of severe aortic stenosis patients, fueled by a large and growing body of evidence on the SAPIEN platform and the increased adoption of SAPIEN 3 Ultra RESILIA.
Within TMTT, strong and increasing utilization of Edwards’ differentiated therapies, combined with double-digit mitral and tricuspid procedure volumes globally, positions Edwards for continued growth. Surgical performance continues to benefit from the ongoing adoption of RESILIA therapies that offer extended durability of Edwards’ therapies, including INSPIRIS, KONECT and MITRIS. Supported by the strong quarterly performance and multiple catalysts, management raised its 2026 outlook.
The contraction in gross margins is a concern, but the expansion in operating margins during the quarter is a positive sign.
EW’s Zacks Rank & Key PicksEdwards Lifesciences currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Tactile Systems Technology, Inc. (TCMD - Free Report) and Phibro Animal Health (PAHC - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted EPS of $1.28, which surpassed the Zacks Consensus Estimate by 20.8%. Revenues of $826.4 million beat the Zacks Consensus Estimate by 4.9%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an earnings yield of 4.7% compared to the industry’s negative 1.4% yield. The company beat earnings estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 18.79%.
Tactile Systems Technology, carrying a Zacks Rank #2 (Buy) at present, posted a fourth-quarter 2025 adjusted EPS of 46 cents, which outpaced the Zacks Consensus Estimate by 3.77%. Revenues of $103.6 million topped the Zacks Consensus Estimate by 10.52%.
TCMD has an earnings yield of 4.4% compared to the industry’s negative 1.4% yield. The company’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 24.85%.
Phibro Animal Health, carrying a Zacks Rank #2 at present, posted a second-quarter fiscal 2026 adjusted EPS of 87 cents, which exceeded the Zacks Consensus Estimate by 27.01%. Revenues of $373.9 million outperformed the Zacks Consensus Estimate by 4.72%.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.1%. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 20.15%.
Modine Manufacturing led the way during the quarter, benefiting from secular demand in data center cooling and a well received spinoff of Modine Manufacturing's auto cooling business. Coming out of 2025, Adeia reported record revenue and profitability, supported by a surge in IP licensing activity. AtriCure remains well positioned given its first-mover advantage and deep integration within surgical workflows despite near-term competitive concerns from Edwards Lifesciences.
LENSAR (NASDAQ:LNSR – Get Free Report) and Edwards Lifesciences (NYSE:EW – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation.
Volatility & Risk LENSAR has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500.
Institutional and Insider Ownership 40.2% of LENSAR shares are held by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are held by institutional investors. 66.0% of LENSAR shares are held by insiders. Comparatively, 0.3% of Edwards Lifesciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation & Earnings This table compares LENSAR and Edwards Lifesciences”s top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LENSAR $58.44 million 1.05 -$34.28 million ($2.90) -1.76 Edwards Lifesciences $6.07 billion 8.00 $1.07 billion $1.83 46.01 Edwards Lifesciences has higher revenue and earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.
Profitability This table compares LENSAR and Edwards Lifesciences’ net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets LENSAR -58.66% N/A -48.11% Edwards Lifesciences 17.39% 14.45% 11.12% Analyst Recommendations This is a summary of recent ratings and recommmendations for LENSAR and Edwards Lifesciences, as provided by MarketBeat.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LENSAR 1 0 2 0 2.33 Edwards Lifesciences 0 9 16 3 2.79 LENSAR presently has a consensus target price of $10.00, suggesting a potential upside of 96.46%. Edwards Lifesciences has a consensus target price of $95.39, suggesting a potential upside of 13.29%. Given LENSAR’s higher probable upside, equities analysts clearly believe LENSAR is more favorable than Edwards Lifesciences.
Summary Edwards Lifesciences beats LENSAR on 12 of the 15 factors compared between the two stocks.
About LENSAR (Get Free Report)
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
About Edwards Lifesciences (Get Free Report)
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient’s heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Receive News & Ratings for LENSAR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENSAR and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEUnisys (NYSE:UIS) vs. Wipro (NYSE:WIT) Financial Analysis
NEXT HEADLINE »Comparing comScore (NASDAQ:SCOR) & International Card Establishment (OTCMKTS:ICRD)
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026. Bernard Zovighian, chief executive officer, will participate in a fireside chat at 3:40 p.m. Pacific Time. A live webcast of the discussion will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com, with an archived version accessible later the same day. About Edwards Lifesciences.
On April 29, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has shown mixed price performance recently. Over the past w
During the quarter, we initiated new positions in Edwards Lifesciences, Eli Lilly and Roblox. In addition to Linde, Shopify and Amazon, we also added to Woodward and Spotify during the quarter. We ended our investment campaigns in Netflix, Snowflake and RELX during the quarter.
CHICAGO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced 10-year results from the COMMENCE aortic trial, reinforcing the long-term durability and sustained performance of its proprietary RESILIA tissue. The data were presented at the 106th American Association for Thoracic Surgery Annual Meeting. As evidence increasingly supports treating patients earlier in the valve disease pathway, the need for durable valve solutions continues to grow. The COMMENCE trial provides prospectiv.
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced the appointment of Theodora (“Doretta”) Mistras as the company's corporate vice president and chief financial officer (CFO), effective at the end of May. Mistras will succeed Scott Ullem, who announced in October his planned transition from the CFO role. Mistras joins Edwards from Viatris, where she has served as CFO since March 2024, leading the company's global finance organization and overseeing financial planni.
Healthcare is regaining momentum as innovation—especially AI‑driven drug discovery—creates new growth opportunities, according to Shivani Vohra. She points to obesity treatments from Eli Lilly (LLY) and Novo Nordisk (NVO), advances in diagnostics from Natera (NTRA), and continued strength in med tech leaders like Intuitive Surgical (ISRG) and Edwards Lifesciences (EW) as key areas of expansion.
On May 11, 2026, Edwards Lifesciences Corp (EW) shares fell 3.5%, bringing the current price to $77.17. The stock has experienced a 52-week range of $72.30 to $
On May 13, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has shown varied price performance recently. The stock has ex
On May 22, 2026, Edwards Lifesciences Corp (EW) shares rose 3.1% to a current price of $85.78. The stock has fluctuated between $72.30 and $87.89 over the past
Vancouver, British Columbia--(Newsfile Corp. - June 12, 2026) - East West Minerals Ltd. (TSXV: EW) ("East West" or the "Company") announces that further to a price reservation filed on June 10, 2026, the Company has arranged a non-brokered private placement financing (the "Financing") of up to 7,800,000 units (each a "Unit"), at a price of $0.11 per Unit, to raise up to $858,000. Each Unit will consist of one common share and one-half of a common share purchase warrant. Each whole warrant will entitle the holder to purchase an additional common share at a price of $0.15 for a period of three years from closing.
Insiders will be participating in this financing and proceeds will be used for working capital purposes. Finder's fees may be payable.
All securities issued in the Financing will be subject to a four-month hold period and to all necessary regulatory approvals, including acceptance of the TSX Venture Exchange.
This press release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the Shares in any jurisdiction in which such offer, solicitation or sale would be unlawful. The Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or the securities laws of any state of the United States, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the U.S. Securities Act) absent registration under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/301244
Source: East West Minerals Ltd.
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
Key Takeaways Edwards' TMTT sales rose about 42% in Q1 2026, driven by the adoption of PASCAL, EVOQUE and SAPIEN M3.Edwards' TAVR sales topped $1B for a sixth straight quarter, growing 11% year over year in Q1 2026.Edwards faces inflation, supply constraints, staffing shortages and foreign exchange headwinds. Edwards Lifesciences (EW - Free Report) appears well-positioned to continue benefiting from the expanding adoption of its premium surgical technologies worldwide. The Transcatheter Mitral and Tricuspid Therapies (“TMTT”) business has seen consistent growth over the past few quarters, which is highly encouraging. The company’s TAVR platform represents another significant growth opportunity, supported by patient activation and advanced new technologies. However, ongoing macroeconomic pressures and currency swings could weigh on Edwards’ financial results.
Over the past year, this Zacks Rank #3 (Hold) stock has gained 13% against the 5.5% fall of the industry and the S&P 500 composite’s 23.8% growth.
The renowned global medical device company has a market capitalization of $49.51 billion. EW’s earnings yield of 3.5% favorably compares with the industry’s negative 3.4% yield. In the trailing four quarters, Edwards delivered an average earnings surprise of 4.8%.
Let’s delve deeper.
Upsides for EW StockSurgical Structural Heart, A Promising Business: The business pioneered the innovative RESILIA tissue, which is backed by more than 40 years of the company’s tissue technology leadership. In first-quarter 2026, the segment grew 6% from the prior-year level, driven by strong global adoption of Edwards’ premium resilient technologies, including INSPIRIS, MITRIS and KONECT. The company continues to see positive procedure growth globally for the many patients treated surgically, including those undergoing complex procedures.
Edwards has been continuously generating evidence to expand the RESILIA portfolio, including positive one-year results from MOMENTIS, supporting the long-term durability of MITRIS systems for surgical mitral valve replacement. It also unveiled favorable eight-year data showing the strong durability of RESILIA tissue bioprosthetic valves.
Image Source: Zacks Investment Research
TMTT Portfolio Holds Potential: To transform care and unlock the significant long-term growth opportunity for mitral and tricuspid patients, Edwards focuses on three key value drivers — a portfolio of differentiated therapies for complex mitral and tricuspid anatomies, positive clinical trial results to support approvals and adoption, and favorable real-world clinical outcomes. In the first quarter of 2026, the segment witnessed an approximately 42% increase in sales compared with the prior year, driven by the continued global adoption of PASCAL, EVOQUE and SAPIEN M3 systems.
Edwards is making strides with the EVOQUE commercial rollout, activating new sites in both the United States and Europe (other than initial trial centers). At the recent ACC session, two-year TRISCEND II data showed EVOQUE significantly reduced all-cause mortality versus medical therapy while delivering sustained TR elimination, improved health and quality of life and no added device-related risk. Owing to a strong global uptake of differentiated therapies, the company now expects to achieve $2.00 billion of sales in 2030.
Solid TAVR Opportunities: Edwards expects TAVR platform growth to be propelled by greater awareness, patient activation, advances in new technologies such as RESILIA, as well as indication expansion and increased global adoption. In the first quarter of 2026, TAVR sales exceeded $1 billion for the sixth consecutive quarter, with 11% year-over-year growth. The performance reflects clinicians' elevated focus on SAPIEN therapy and proactive disease management of patients suffering from severe aortic stenosis. Edwards' strong competitive position and average selling prices remained stable globally.
Europe’s sales benefited from healthy underlying TAVR procedure growth. The updated guidelines from the European Society of Cardiology and the European Association for Cardiothoracic Surgery are also reinforcing the role of TAVR for a broader patient population. Outside Europe, sales grew strongly across several regions, including Japan, driven by rising procedure volumes and increased adoption of the SAPIEN 3 Ultra RESILIA platform.
What Ails Edwards?Macro Concerns Put Pressure on the Bottom Line: Edwards’ extensive global operations and overseas manufacturing facilities and suppliers bring certain financial, economic, political and other risks. The global economy continues to experience volatility and disruptions, including conditions impacting inflation, credit and capital markets, interest rates and factors influencing overall economic stability and the political environment relating to health care. Persistent inflationary pressure, supply constraints stemming from geopolitical complications and regulatory changes are weighing heavily on the company’s operating results. Hospital staffing shortages remain another bottleneck.
Foreign Exchange Headwinds: Foreign exchange is a major headwind for Edwards due to a considerable percentage of its revenues coming from outside the United States (in 2025, 41.6% of the company’s net sales were derived from international regions). We remain worried about the significant challenges Edwards had to face owing to the unfavorable foreign currency impact that has been adversely affecting the company’s gross margin over the past few quarters.
EW Stock Estimate TrendThe Zacks Consensus Estimate for Edwards’ 2026 earnings per share (EPS) has remained constant at $3.00 in the past 30 days.
The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $6.74 billion, suggesting an 11.1% improvement from the year-ago reported number.
Key PicksSome better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Align Technology (ALGN - Free Report) and Integra LifeSciences (IART - Free Report) .
Globus Medical has an earnings yield of 5.9% compared to the industry’s negative 3.2% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 26.3%. GMED shares have rallied 33.8% against the industry’s 5.5% fall over the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technology, sporting a Zacks Rank #1, has an estimated long-term earnings growth rate of 10.3% compared with the industry’s 9.6% growth. Shares of the company have dropped 2.9% against the industry’s 6.9% rise. ALGN’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 7.8%.
Integra LifeSciences, carrying a Zacks Rank #2 (Buy), has an earnings yield of 14.2% against the industry’s negative 3.2% yield. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 16.7%. IART shares have rallied 37.9% against the industry’s 5.5% decline over the past year.
